Literature DB >> 29174192

Implementation of an antimicrobial stewardship program for patients with febrile neutropenia.

Bahar Madran1, Şiran Keske1, Gizem Tokça1, Ebru Dönmez1, Burhan Ferhanoğlu2, Mustafa Çetiner3, Nil Molinas Mandel4, Önder Ergönül5.   

Abstract

BACKGROUND: We aimed to describe the effectiveness of our standardized protocol for febrile neutropenia (FN), which was targeted to minimize unintended outcomes and reduce antimicrobial consumption.
METHODS: The study was performed in a private hospital with 300 beds. We included all adult hematologic and oncologic cancer inpatients admitted between January 1, 2015-December 31, 2015, and January 1, 2016-May 31, 2017. The outcomes of the study were fatality, infections, and adherence to the antimicrobial stewardship program (ASP).
RESULTS: We included 152 FN attacks of 95 adult inpatients from hematology and oncology wards; of these, 43% were women, and the median age was 57 years. The case fatality rate was 30% in the pre-ASP period and decreased to 11% in the post-ASP period (P = .024). The appropriate adding or changing (P = .006) and appropriate continuation or de-escalation or discontinuation of antimicrobials improved (P < .001). In the post-ASP period, Staphylococcus spp infections (from 22% to 8%, P = .02) and gram-negative infections decreased (from 43% to 20%, P = .003). In the multivariate analysis, appropriate continuation or de-escalation or discontinuation was increased in the post-ASP period (odds ratio [OR], 4.3; 95% confidence interval [CI], 1.82-10.41; P = .001), and gram-positive infections were decreased (OR, 0.32; 95% CI, 0.11-0.95, P = .041). Vancomycin and fluoroquinolone use decreased significantly.
CONCLUSIONS: After implementation of the ASP, the case fatality rate among the patients with FN decreased. Appropriate antimicrobial use increased and overall antimicrobial consumption was reduced. Bacterial infections and Candida infections decreased.
Copyright © 2018 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Febrile; antimicrobial; neutropenia; outcome; stewardship

Mesh:

Substances:

Year:  2017        PMID: 29174192     DOI: 10.1016/j.ajic.2017.09.030

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  5 in total

1.  Antimicrobial Stewardship in Hematological Patients at the intensive care unit: a global cross-sectional survey from the Nine-i Investigators Network.

Authors:  Jordi Rello; Cristina Sarda; Djamel Mokart; Kostoula Arvaniti; Murat Akova; Alexis Tabah; Elie Azoulay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-11-09       Impact factor: 3.267

2.  Standardizing Febrile Neutropenia Management: Antimicrobial Stewardship in the Hematologic Malignancy Population.

Authors:  John C O'Horo; Jasmine R Marcelin; Omar M Abu Saleh; Amelia K Barwise; Patricia M Odean; Christina G Rivera; Aaron J Tande; John W Wilson; Douglas R Osmon; Pritish K Tosh
Journal:  J Oncol Pract       Date:  2019-07-19       Impact factor: 3.840

3.  Pharmacist-Driven Antibiotic Stewardship Program in Febrile Neutropenic Patients: A Single Site Prospective Study in Thailand.

Authors:  Kittiya Jantarathaneewat; Anucha Apisarnthanarak; Wasithep Limvorapitak; David J Weber; Preecha Montakantikul
Journal:  Antibiotics (Basel)       Date:  2021-04-17

4.  Long-Term Impact of an Educational Antimicrobial Stewardship Program on Management of Patients with Hematological Diseases.

Authors:  Ana Belén Guisado-Gil; Manuela Aguilar-Guisado; Germán Peñalva; José Antonio Lepe; Ildefonso Espigado; Eduardo Rodríguez-Arbolí; José González-Campos; Nancy Rodríguez-Torres; María Isabel Montero-Cuadrado; José Francisco Falantes-González; Juan Luis Reguera-Ortega; María Victoria Gil-Navarro; José Molina; José-Antonio Pérez-Simón; José Miguel Cisneros
Journal:  Antibiotics (Basel)       Date:  2021-01-30

5.  Antibiotic Stewardship Program Experience in a Training and Research Hospital.

Authors:  Emel Eksi Alp; Ahsen Oncul; Nazan Dalgic; Cem Akgun; Elif Aktas; Banu Bayraktar
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2021-07-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.